Can the startup win approval of an ALS drug submitted through a fresh analysis of data from old studies, or will it have to perform a new, expensive and time-consuming study of its own?
Old drug, reworked data, new gov’t push define Peninsula company’s attack on ALS
Can the startup win approval of an ALS drug submitted through a fresh analysis of data from old studies, or will it have to perform a new, expensive and time-consuming study of its own?
